SAN DIEGO--(BUSINESS WIRE)--Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Roka Bioscience, Inc. (NASDAQ: ROKA) and certain of its officers. Roka Bioscience is a molecular diagnostics Company focusing on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens.
Specifically, Johnson & Weaver’s investigation seeks to determine whether certain statements regarding the Company’s business and prospects were false and misleading when made.
On July 17, 2014 Roka Bioscience stock opened for trading at $12.00 the day the Company sold 5.0 million shares of stock in its initial public stock offering (the “IPO”), reaching a high of $13.00 per share the following day. However, just several months after its IPO, on November 6, 2014, the company announced that it lost 64 cents a share in the third quarter. Additionally, the Company reported that there were no new Atlas® instruments placements made during the quarter. This news sent the Company’s stock price plummeting, closing at $3.00 per share on November 7, 2014, a decline of $5.34 per share or 64%.
If you have information that could assist in this investigation, or if you are a Roka Bioscience shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (firstname.lastname@example.org) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.